產(chǎn)品名稱：Everolimus 產(chǎn)品貨號：LC E-4040 產(chǎn)品規(guī)格：10 MG Everolimus is an immunosuppressant analog of rapamycin (sirolimus) and inhibits growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Chapman, T.M. and Perry, C.M. "Everolimus." Drugs 64: 861-874 (2004). Everolimus shows a potent inhibitory effect on posttransplant lymphoproliferative disorder (PTLD)-derived cells in vitro and in vivo, in a dose range that can prevent allograft rejection, and may demonstrate activity in both the prevention and treatment of PTLDs in transplant patients. Majewski, M., et al. "Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses." Transplantation 75: 1710-1717 (2003). Oral everolimus inhibits in-stent neointimal growth in the rabbit iliac artery. Everolimus was well tolerated at a dose of 1.5 mg/kg given 1 day before stenting followed by 0.75 mg/kg per day for 28 days and was related with significant neointimal healing. Farb, A., et al. "Oral Everolimus Inhibits In-Stent Neointimal Growth." Circulation 106: 2379-2384 (2002). Everolimus is the active ingredient in the drug sold under the tradenames Afinitor®, Certican®, and Zortress® and in the drug-eluting stent sold under the tradename XienceV®. The drug has been approved in at least one country for prophylaxis of organ rejection in patients who have received a kidney or heart transplant, and the stent has been approved in at least one country for use in patients undergoing angioplasty. NOTE: The everolimus sold by LC Laboratories is NOT Certican® or XienceV®, and is NOT for human use. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A
滬公網(wǎng)安備 31011002002623號
